# Surgery Partners, Inc. (SGRY): Growth Potential with a 64% Upside and Strong Buy Ratings

- Link: https://www.directorstalkinterviews.com/surgery-partners-inc-sgry-growth-potential-with-a-64-upside-and-strong-buy-ratings/4121241321
- Published: 2026-02-24T11:29:23+00:00
- Author: Madison Wilson

Surgery Partners, Inc. (NASDAQ: SGRY) is garnering significant attention from investors,
fueled by promising analyst ratings and a compelling potential upside. Operating
within the dynamic healthcare sector, this company specializes in medical care facilities,
particularly focusing on non-emergency surgical procedures across a range of specialties.
Headquartered in Brentwood, Tennessee, Surgery Partners has demonstrated a robust
presence in the United States healthcare landscape since its founding in 2004.

As of now, Surgery Partners maintains a market capitalization of $2 billion, with
its stock priced at $15.49, a slight dip from the previous trading session. The 
stock’s 52-week range spans from $13.43 to $25.44, indicating some volatility, yet
this also presents opportunities for strategic investors. Currently, the stock hovers
near the lower end of this range, suggesting a potential entry point for those looking
to capitalize on its growth prospects.

Valuation metrics reveal some gaps, as traditional measures such as the trailing
P/E ratio and PEG ratio are not applicable. However, the forward P/E ratio stands
at 22.50, providing a glimpse into future earnings potential. Investors should also
note that the company’s price/book and price/sales ratios are not available, requiring
a deeper dive into alternative metrics for valuation insights.

Despite these valuation challenges, Surgery Partners has shown revenue growth of
6.60%, a positive indicator amidst the complex healthcare environment. The company’s
earnings per share (EPS) is currently at a negative $1.36, reflecting ongoing investments
and growth strategies. Yet, its return on equity (ROE) is a modest 0.66%, while 
free cash flow is strong at over $131 million, underscoring its financial flexibility.

Importantly, Surgery Partners does not currently offer a dividend, with a payout
ratio of 0.00%, aligning with its strategy to reinvest earnings into expanding operations
and enhancing service offerings.

Analyst sentiment is notably favorable, with nine buy ratings and three hold ratings,
and no sell recommendations. The target price range for SGRY is between $18.00 and
$33.00, with an average target of $25.45, pointing to a potential upside of approximately
64.33% from the current price level. This optimism reflects confidence in the company’s
strategic direction and market positioning.

Technical indicators provide additional insights for investors. The stock’s 50-day
moving average is $15.39, slightly below the current price, while the 200-day moving
average is $19.86, highlighting the stock’s recent downward trend. The Relative 
Strength Index (RSI) is at 26.07, suggesting the stock is oversold and may be poised
for a rebound. The MACD and signal line, at 0.01 and -0.18 respectively, further
illustrate a potential shift in momentum.

Surgery Partners’ business model, centered around surgical facilities and ancillary
services, positions it well in the ever-evolving healthcare sector. Its network 
of ambulatory surgery centers and hospitals provides vital non-emergency procedures,
catering to specialties such as orthopedics, ophthalmology, gastroenterology, and
more. The company’s focus on both single- and multi-specialty facilities enhances
its adaptability and service reach.

For investors, Surgery Partners, Inc. offers a blend of growth potential and strategic
market positioning, supported by strong analyst endorsements. While challenges remain,
particularly in achieving consistent profitability, the company’s robust cash flow
and promising upside make it an intriguing consideration for those looking to invest
in the healthcare sector.

Share on: